Skip to main
CRVO
CRVO logo

CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed Inc (CRVO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CervoMed Inc. has demonstrated a positive financial trajectory, evidenced by a strengthened cash position of $38.9 million as of December 31, 2024, which supports its operational runway into mid-2026. The encouraging results from the 16-week extension phase of the RewinD-LB Phase 2b trial for neflamapimod show statistically significant clinical benefits, enhancing the company’s outlook for successful treatment of dementia with Lewy bodies. With increased investment in research and development, reflected in R&D expenses rising to $18.8 million, CervoMed is well-positioned for continued clinical advancement and corporate development.

Bears say

CervoMed Inc has experienced setbacks in its clinical trials, particularly with the RewinD-LB study, where suboptimal drug concentrations in trial capsules led to disappointing initial results. The company faces significant financial risks as it has yet to generate revenue from any marketable products and has consistently incurred losses since its inception. Additionally, there is heightened competition from both existing and emerging therapies addressing similar conditions, which could further hinder CervoMed's ability to penetrate the market and achieve sustainable pricing.

CervoMed Inc (CRVO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CervoMed Inc (CRVO) Forecast

Analysts have given CervoMed Inc (CRVO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, CervoMed Inc (CRVO) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CervoMed Inc (CRVO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.